Research at the interface of industry, academia and regulatory science

Nature Biotechnology

Volumn 28, Issue 5, 2010, Pages 432-433

  Mattes, William B ^a   Walker, Elizabeth Gribble ^a   Abadie, Eric ^b   Sistare, Frank D ^c   Vonderscher, Jacky ^d   Woodcock, Janet ^e   Woosley, Raymond L ^a  

^a CRITICAL PATH INSTITUTE   (United States)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Novartis   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; EDITORIAL; FOOD AND DRUG ADMINISTRATION; INDUSTRY; PRIORITY JOURNAL; SCIENTIFIC LITERATURE;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG INDUSTRY; EUROPE; HUMANS; KIDNEY; PHARMACEUTICAL PREPARATIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; UNIVERSITIES;

EID: 77952130327     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0510-432     Document Type: Editorial

References (28)

1. Borchers A.T., Hagie F., Keen C.L., Gershwin M.E. Clin. Ther. 29, 1-16 (2007).
2. Miller, S.A. J. Nutr. 123, 279-284 (1993).
3. Collins, J.M. Chem. Biol. Interact. 134, 237-242 (2001).
4. Peters, T.S. Toxicol. Pathol. 33, 146-154 (2005).
5. Voisin, E.M., Ruthsatz, M., Collins, J.M. & Hoyle, P.C. Regul. Toxicol. Pharmacol. 12, 107-116 (1990).
6. Jacobs, A. & Jacobson-Kram, D. Toxicol. Sci. 81, 260-262 (2004).
7. Jacobson-Kram, D. & Contrera, J.F. Toxicol. Sci. 96, 16-20 (2007).
8. Miller, M.A. Int. J. Toxicol. 20, 149-152 (2001).
9. MacGregor, J.T. Toxicol. Sci. 75, 236-248 (2003).
10. Tong, W. et al. Environ. Health Perspect. 111, 1819-1826 (2003).
11. Gutman, S. & Kessler, L.G. Nat. Rev. Cancer 6, 565-571 (2006).
12. Lesko, L.J. Clin. Pharmacol. Ther. 81, 807-816 (2007).
13. Anonymous. Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (FDA, Washington, DC, 2004; accessed 23 April 2010). http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262.htm
14. Woosley, R.L. & Cossman, J. Clin. Pharmacol. Ther. 81, 129-133 (2007).
15. Anonymous. US Food and Drug Administration. Critical Path Opportunities List-March 2006 (FDA, Washington, DC, 2006; accessed 23 April 2010). http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077258.pdf
16. Irwin, D.A. & Klenow, P.J. Proc. Natl. Acad. Sci. USA 93, 12739-12742 (1996)
17. The Food and Drug Adminstration. Fed. Regist. 70, 74823-74826 (2005).
18. Marrer, E. & Dieterle, F. Chem. Biol. Drug Des. 69, 381-394 (2007)
19. Mattes, W.B. Methods Mol. Biol. 460, 221-238 (2008).
20. Kim, W.R., Flamm, S.L., Di Bisceglie, A.M. & Bodenheimer, H.C. Hepatology 47, 1363-1370 (2008).
21. Zweig, M.H. & Campbell, G. Clin. Chem. 39, 561-577 (1993)
22. Senior, J.R. Clin. Liver Dis. 11, 507-524 (2007)
23. The Food and Drug Adminstration. Fed. Regist. 72, 60681-60682 (2007).
24. Wagner, J.A., Williams, S.A. & Webster, C.J. Clin. Pharmacol. Ther. 81, 104-107 (2007).
25. Lee, J.W. et al. Pharm. Res. 23, 312-328 (2006).
26. Wagner, J.A. Annu. Rev. Pharmacol. Toxicol. 48, 631-651 (2008).
27. Goodsaid, F.M., Frueh, F.W. & Mattes, W. Toxicology 245, 219-223 (2008).
28. Schetz, M., Dasta, J., Goldstein, S. & Golper, T. Curr. Opin. Crit. Care 11, 555-565 (2005).